As of December 31, 2025, Galderma Group AG carries a market capitalization of 41.00B, placing it among publicly traded companies globally. Its enterprise value stands at 42.68B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 41.00B |
| Enterprise Value | 42.68B |
As of December 31, 2025, Galderma Group AG has 234.57M shares outstanding.
| Shares Outstanding | 234.57M |
These figures are as of December 31, 2025.
| PB Ratio | 5.91 |
| P/TBV Ratio | -29.75 |
As of December 31, 2025, Galderma Group AG maintains a current ratio of 1.19, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.19 |
| Quick Ratio | 0.38 |
| Debt / Equity | 33.80 |
These figures cover the twelve months ended December 31, 2025.
| Employee Count | 7,110.50 |
As of the close on October 6, 2026, Galderma Group AG's stock has gained approximately 13.82% over the past 52 weeks. The 50-day moving average sits at 178.12, while the 200-day moving average is 175.18.
| 52-Week Price Change | 13.82% |
| 50-Day Moving Average | 178.12 |
| 200-Day Moving Average | 175.18 |
As of December 31, 2025, Galderma Group AG holds 663.86M in cash and equivalents against 2.34B in total debt, resulting in a net debt position of 1.55B. Total book value stands at 6.94B, with working capital of 325.12M providing operational flexibility.
| Cash & Cash Equivalents | 663.86M |
| Total Debt | 2.34B |
| Net Debt | 1.55B |
| Equity (Book Value) | 6.94B |
| Book Value Per Share | 29.57 |
| Working Capital | 325.12M |
Already premium?